直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

In Amazon v. Audio Pod, Acting Director Hits Pause on Young Patent When Older Patents Dominate the Playlist

October 1, 2025

Authored and Edited by Forrest A. Jones; Jameson K. Gardner, Ph.D.; Comfort O. Adeyemi

Acting Director Coke Morgan Stewart denied institution of all six Petitions in Amazon.com, Inc., Amazon.com Services LLC, Amazon Web Services, Inc., and Audible, Inc. v. Audio Pod IP, LLC, IPR2025-00757, IPR2025-00765, IPR2025-00768, IPR2025-00769, IPR2025-00774, IPR2025-00777, Paper 15 (PTAB Aug.14, 2025) on the basis of efficient use of Board resources, even though one of the challenged patents had only been in force since 2020.

At the time of the decision, five of the challenged patents had been in force for at least seven years, while the sixth—U.S. Patent No. 10,805,111 (“the ’111 patent”)—had been in force for four years. For the five older patents, the Acting Director found that their age created “strong settled expectations” and that Petitioners had been aware of these patents for a significant period before filing their Petitions. While acknowledging that the shorter enforcement period for the ’111 patent would typically weigh against discretionary denial, the Acting Director explained that instituting a separate IPR solely for the ’111 patent would have been an “inefficient use of Board resources.” The Acting Director also noted that all six patents were the subject of a parallel district court case, and as such, the validity of the patents would be assessed in that proceeding.

In contrast to Amgen Inc. v. Bristol-Myers Squibb Company, IPR2025-00603, Paper 8 (PTAB Jul. 24, 2025), where institution was denied for two patents that were at least six years old but a third patent that was only three years old was referred to the Board because it had not yet developed “strong settled expectations,” here, the Acting Director did not determine whether the ’111 patent had itself developed strong settled expectations. Instead, the Acting Director determined that institution would not be an efficient use of Board resources despite the lack of settled expectations for the ’111 patent, suggesting that related patents may sometimes rise and fall together, regardless of age.

Tags

United States Patent and Trademark Office (USPTO), discretionary denials

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

AI, Electronics, and Information Technology

Web3

Communications

Media

Related Offices

Reston, VA

Washington, DC

Contacts

Forrest A. Jones
Partner
Washington, DC
+1 202 408 4019
Email
Jameson K. Gardner, Ph.D.
Associate
Reston, VA
+1 571 203 2425
Email
Comfort O. Adeyemi
Associate
Washington, DC
+1 202 408 4233
Email

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Virtual Seminar

Patent "Basics" Seminar

May 19, 2026

Virtual

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP